---
figid: PMC3978385__nihms-570892-f0003
figtitle: 'NRAS mutant melanoma: biological behavior and future strategies for therapeutic
  management'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3978385
filename: nihms-570892-f0003.jpg
figlink: /pmc/articles/PMC3978385/figure/F3/
number: F3
caption: A. In normal melanocytes, cyclic AMP pathway activation promotes PKA-mediated
  inhibition of CRAF. Therefore MAPK signaling proceeds through BRAF rather than CRAF
  in these cells (left panel). B. In NRAS mutant melanoma, inhibition of PKA signaling
  due to enzymatic activity of phosphodiesterase (PDE) and negative feedback inhibition
  of BRAF due to activation of the MAPK pathway promotes CRAF-mediated MAPK signaling
  instead (right panel).
papertitle: 'NRAS mutant melanoma: biological behavior and future strategies for therapeutic
  management.'
reftext: Inna V. Fedorenko, et al. Oncogene. ;32(25):3009-3018.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9592405
figid_alias: PMC3978385__F3
figtype: Figure
redirect_from: /figures/PMC3978385__F3
ndex: fd632b34-deab-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3978385__nihms-570892-f0003.html
  '@type': Dataset
  description: A. In normal melanocytes, cyclic AMP pathway activation promotes PKA-mediated
    inhibition of CRAF. Therefore MAPK signaling proceeds through BRAF rather than
    CRAF in these cells (left panel). B. In NRAS mutant melanoma, inhibition of PKA
    signaling due to enzymatic activity of phosphodiesterase (PDE) and negative feedback
    inhibition of BRAF due to activation of the MAPK pathway promotes CRAF-mediated
    MAPK signaling instead (right panel).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CG2224
  - ras
  - Ras64B
  - Ras85D
  - PDZ-GEF
  - garz
  - RhoGEF64C
  - pbl
  - drk
  - ac
  - ATPsynbeta
  - Atpalpha
  - gy
  - gb
  - Gbeta5
  - Gbeta13F
  - Gbeta76C
  - dnc
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - Cp15
  - Dsor1
  - Mtk
  - CrebB
  - CrebA
  - Mitf
  - Erk7
  - rl
  - Tie
  - InR
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - STAMBP
  - KRAS
  - HRAS
  - NRAS
  - ARHGEF2
  - SLC2A4RG
  - GRB2
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - ATP8A2
  - SUCLG2
  - GNB1
  - GNB2
  - GNB3
  - GNB4
  - GNB5
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - BRAF
  - RAF1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - MITF
  - EPHB2
  - MAPK1
  - MAPK3
  - Cardiomyopathy
  - Noonan syndrome
---
